Assertio Holdings, Inc. (ASRT)

NASDAQ: ASRT · IEX Real-Time Price · USD
2.13
-0.06 (-2.74%)
At close: Jan 25, 2022 4:00 PM
2.18
0.05 (2.35%)
After-hours:Jan 25, 2022 7:58 PM EST
Market Cap95.07M
Revenue (ttm)107.86M
Net Income (ttm)-30.24M
Shares Out44.63M
EPS (ttm)-0.78
PE Ration/a
Forward PE7.15
Dividendn/a
Ex-Dividend Daten/a
Volume551,468
Open2.14
Previous Close2.19
Day's Range2.10 - 2.25
52-Week Range0.85 - 5.80
Beta1.66
AnalystsBuy
Price Target4.00 (+87.8%)
Earnings Daten/a

About ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of mi...

IndustryPharmaceuticals
IPO DateNov 5, 1997
Employees27
Stock ExchangeNASDAQ
Ticker SymbolASRT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 4.00, which is an increase of 87.79% from the latest price.

Price Target
$4.00
(87.79% upside)
Analyst Consensus: Buy

News

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

2 weeks ago - Zacks Investment Research

Despite Fast-paced Momentum, Assertio (ASRT) Is Still a Bargain Stock

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that mad...

4 weeks ago - Zacks Investment Research

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Assertio Holdings, Inc. for Potential Breaches of F...

NEW YORK, Dec. 27, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

4 weeks ago - PRNewsWire

Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Assertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44M

Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT) for $44 million inclusive of Otrexup WIP...

1 month ago - Benzinga

Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares P...

Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million

1 month ago - GlobeNewsWire

Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that mad...

2 months ago - Zacks Investment Research

Assertio Holdings, Inc. Announces Preliminary Court Approval of Shareholder Derivative Settlement

LAKE FOREST, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that on October 28, 2021, the Superior Court of the State of Cal...

2 months ago - GlobeNewsWire

Assertio Posts Higher Profitability In Q3 Despite Lower Revenues

Assertio Holdings Inc (NASDAQ: ASRT) posted Q3 sales of $25.9 million, down 23% Y/Y, but surpassed the consensus of $22.04 million. Assertio's restructuring plan resulted in cost savings of $40.0 millio...

2 months ago - Benzinga

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 300.00% and 15.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Assertio Holdings, Inc. to Report Third Quarter 2021 Financial Results After the Close of Markets on Thursday, Novemb...

LAKE FOREST, Ill., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release third quarter 2021 financial results on Thu...

2 months ago - GlobeNewsWire

Assertio Holdings, Inc. to Participate in Upcoming Investor Events

LAKE FOREST, Ill., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company's Chief Executive Officer, Dan Peisert, and Chi...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for September 9th

ASRT, CVGW, NTRB, ITRG, and KNBWY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2021

Other symbols:CVGWITRGNTRB
4 months ago - Zacks Investment Research

New Strong Sell Stocks for September 7th

ASRT, GLDD, MOGO, XPO, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on September 7, 2021

Other symbols:GLDDMOGOXPO
4 months ago - Zacks Investment Research

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of -300.00% and 24.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Assertio Reports Second Quarter 2021 Financial Results

Reported Net Product Sales of $24.8 Million

5 months ago - GlobeNewsWire

Assertio (ASRT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

LAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qua...

7 months ago - GlobeNewsWire

Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options

Investors need to pay close attention to for Assertio Holdings (ASRT) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split

LAKE FOREST, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has filed a Certificate of Amendment to its certificate o...

8 months ago - GlobeNewsWire

Assertio Holdings, Inc. Announces Adjournment of Annual Meeting of Shareholders

- Adjournment Solely to Vote on the Reverse Split and Proportional Authorized Shares Reduction Proposal (Proposal 2) and Increase in Authorized Shares Proposal (Proposal 3)

8 months ago - GlobeNewsWire

3 Penny Stocks That Investors Need to Watch In 2021

Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |...

Other symbols:ACSTTTOO
8 months ago - PennyStocks

Assertio Reports First Quarter 2021 Financial Results

Reported Net Product Sales of $26.4 Million, Compared to Prior Year Pro-Forma Net Products Sales of $28.3 Million

8 months ago - GlobeNewsWire

Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Dig...

Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, and Continuous Online Physician Care Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, a...

8 months ago - GlobeNewsWire